Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00362973 · ClinicalTrials.gov registry record
PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer
A clinical trial, sponsored by University of Washington.
- Completed
- Registry status
- 42
- Enrollment target
NCT00362973 is a clinical trial that has completed, run by University of Washington. The registered enrollment target is 42 participants.
The verdict
NCT00362973 has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Diagnostic procedures, such as PET scans, may help in learning how well hormone therapy and trastuzumab work to kill breast cancer cells and allow doctors to plan better treatment. PURPOSE: This clinical trial is studying how well PET scans work in assessing response to treatment in patients receiving hormone therapy or trastuzumab for breast cancer.
Interventions
- OTHER laboratory biomarker analysis
- RADIATION fludeoxyglucose F 18
- PROCEDURE positron emission tomography
- PROCEDURE radionuclide imaging
- PROCEDURE needle biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2006-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00362973
The ClinicalTrials.gov registry entry for NCT00362973 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00362973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00362973 about?
NCT00362973 is a clinical study titled "PET Scans in Assessing Response To Treatment in Patients Receiving Hormone Therapy or Trastuzumab for Breast Cancer". RATIONALE: Diagnostic procedures, such as PET scans, may help in learning how well hormone therapy and trastuzumab work to kill breast cancer cells and allow doctors to plan better treatment. PURPOSE: This clinical trial is studying how well PET scans work in assessing response to treatment in pati...
What is the current status of trial NCT00362973?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2006-05.
What interventions are being tested in trial NCT00362973?
The interventions under investigation include: laboratory biomarker analysis (OTHER), fludeoxyglucose F 18 (RADIATION), positron emission tomography (PROCEDURE), radionuclide imaging (PROCEDURE), needle biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT00362973?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.